The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Approved just three weeks ago to treat hemophilia B, CSL Behring and uniQure’s gene therapy Hemgenix carries the highest price tag ever for a drug at $3.5 million. Now it is up to CSL to prove that ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. On November 22 nd, the Food and Drug Administration (FDA) approved ...
Global biotechnology leader CSL Behring announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene ...
The Food and Drug Administration has approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor ...
On Tuesday, November 22nd, 2022, the United States Food and Drug Administration approved Hemgenix, a new drug to treat hemophilia. Hemophilia is a lifelong & rare blood disorder where the blood cannot ...
UniQure will sell a portion of the royalty rights due to it from CSL Behring from the net sales of Hemgenix The gross purchase price is up to $400 million in cash UniQure is an Amsterdam-based gene ...
94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results